Brucella abortus RB51: enhancing vaccine efficacy and developing multivalent vaccines

Area of Science:

• Veterinary immunology
• Vaccine development
• Bacterial pathogenesis

Background:

• Brucella abortus vaccine strain RB51 is a key tool for controlling bovine brucellosis.
• Overexpressing Cu-Zn superoxide dismutase (SOD) enhances RB51 vaccine efficacy.
• RB51 can be engineered for heterologous protein expression, inducing Th1 immune responses.

Purpose of the Study:

• To develop novel recombinant RB51 vaccines combining enhanced brucellosis protection with simultaneous protection against Mycobacterium spp.
• To generate and evaluate recombinant RB51 strains expressing mycobacterial antigens.

Main Methods:

• Constructed two recombinant RB51 strains: RB51SOD/85A (overexpressing SOD and Mycobacterium 85A antigen) and RB51ESAT (expressing ESAT-6 fusion protein).
• Vaccinated mice with recombinant strains and control RB51.
• Assessed immune responses to mycobacterial antigens and protection against Brucella challenge.

Main Results:

• Mice vaccinated with recombinant strains showed specific immune responses to mycobacterial antigens (85A and ESAT-6).
• Recombinant RB51 vaccines provided significantly enhanced protection against Brucella challenge compared to RB51 alone.
• The engineered vaccines demonstrated potential for dual protection against Brucella and Mycobacterium infections.

Conclusions:

• Recombinant RB51 strains engineered to express mycobacterial antigens and SOD offer improved protection against brucellosis.
• These novel vaccines induce specific immune responses to foreign antigens, suggesting potential for multi-pathogen vaccines.
• Further research into these dual-purpose vaccines could advance bovine and potentially human health.